37, 38 However, the extent to which this system plays a role in human hepatitis B, especially fulminant hepatitis, is unknown. As shown in this study (Fig. 5A), inhibition of the Fas/FasL system by anti-Fas antibody dramatically reduced the effect of human PBMC transplantation. This showed the possibility that the Fas/FasL system plays an important role in the degeneration of infected hepatocytes in FHB. Further studies should be conducted to evaluate what immunological responses play important roles in human hepatitis B. The importance of NK-cell activity suggests that MK-2206 cell line the suppression of DCs

and NK-cell activity or the Fas/FasL system might have therapeutic implications for FHB.11, 35 If DCs and NK-cell activity or Fas/FasL activity could be controlled in the early stages of severe acute or fulminant hepatitis, we might be able to control hepatitis activity and prevent subsequent liver failure. Of course, it would be necessary to monitor the development of chronic hepatitis after such treatment because DCs and NK cells contribute to early host defenses and shape subsequent adaptive immune response through complex cross-talk regulating the early phase

of the immune response.19, 24, 39, 40 We analyzed liver damage using HBV genotype C–infected mice in this study. However, HBV genotype C is associated with more severe histological liver damage than genotype B,41 and future studies should compare immunological differences between genotypes B and C. In summary, we established an animal Small Molecule Compound Library model of FHB using highly repopulated human hepatocyte chimeric mice and transplanted human PBMCs. Modifications of this model will facilitate further research into acute and CHB using human immune cells, including HBV-directed

CTL clones, suppressor and regulatory T cells, MCE as well as immunological experiments to study interactions between DCs and NK cells. Such models may be useful to develop and evaluate new therapeutic strategies against HBV infection. The authors thank Rie Akiyama and Yoko Matsumoto for their expert technical assistance. This work was carried out at the Analysis Center of Life Science, Natural Science Center for Basic Research and Development, Hiroshima University. Additional Supporting Information may be found in the online version of this article. “
“Background: Recently, long-term low dose of carvedilol has suggested an option for primary prophylaxis of bleeding in patients with high-risk esophageal varices. The aim of this study is to evaluate and compare the effect of carvediolol versus propranolol on reduction in portal pressure in patients with cirrhosis. Methods: We conducted this ongoing prospective randomized multicenter study (target sample size: 130 patients) between July 2011 and February 2013 and analyzed clinical and hemodynamic measurement data of 99 cirrhotic patients with high-risk esophageal varices and severe portal hypertension (HVPG > 12 mmHg).

No related posts.